Rye Brook Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rye Brook Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$205K	Buy	+1,300	New	+$205K	0.13%	40
2021 Q2	–	Sell	-23,100	Closed	-$3.13M	–	29
2021 Q1	$3.13M	Buy	23,100 +4,900	+27%	+$734K	2.28%	16
2020 Q4	$2.56M	Buy	+18,200	New	+$2.33M	2.23%	16

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $20.7B AUM 58.31% 1-Year Est. Return

Employees Retirement System of Texas Austin, Texas $12.2B AUM 27.55% 1-Year Est. Return

Rye Brook Capital's XBI Position: Q3 2026 in Review

Rye Brook Capital opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 1,300 shares worth $205K. The stake represents 0.13% of the portfolio and ranks #40 among its holdings. This is a return to the name: Rye Brook Capital previously reported a position in XBI as recently as Q1 2021.

Rye Brook Capital first reported a position in XBI in Q4 2020 and has held it in 3 quarters since. The position peaked at $3.13M in Q1 2021. 647 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Rye Brook Capital held 1,300 shares of State Street SPDR S&P Biotech ETF worth $205K as of Q3 2026.
State Street SPDR S&P Biotech ETF was a new Rye Brook Capital position in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.13% of Rye Brook Capital's portfolio in Q3 2026, its #40 holding.
Rye Brook Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and has held it in 3 quarters since.
Rye Brook Capital's State Street SPDR S&P Biotech ETF position peaked at $3.13M in Q1 2021.
647 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Rye Brook Capital's 13F filing for Q3 2026, filed 7 Oct 2026.